February 15, 2024
EQT is entertaining exit dialogues with international investment banks for Karo Healthcare, a provider of OTC and prescription pharmaceuticals as well as medical devices, with sources pointing towards the possibility of a process launching as early as H2-2024 - pro-forma EBITDA of SEK +1,000m in FY23E (NKP Proprietary)
NKP | M&A Insights Proprietary
Headline from pre-deal coverage in M&A Insights
.png){kind=logo}